Compare BIO-TECHNE Corp (TECH) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs United Microelectronics Corp — how do they compare? BIO-TECHNE Corp trades at $71.79 (market cap $11.16B), while United Microelectronics Corp trades at $21.17 (market cap $51.00B). The key difference: United Microelectronics Corp is far larger — about 4.6× BIO-TECHNE Corp's market cap, and United Microelectronics Corp pays the higher dividend (2.03%). Which is the better fit depends on your goals.
| TECH | UMC | |
|---|---|---|
Market Cap | $11.16B | $51.00B |
Sector | Health | Technology |
52-Week High | $72.12 | $28.02 |
52-Week Low | $43.31 | $6.58 |
Enterprise Value | $11.24B | $48.57B |
Dividend Yield | 0.45% | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
UMC trades at $20.41, down 3.95% for the day, with a bearish technical signal but oversold RSI readings. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains strong profitability with a 20.25% net margin. Recent news highlights mass production of silicon photonics ICs and a new 14nm eHV platform, signaling innovation in semiconductor technology.
Outlook is mixed: analyst consensus leans Hold (53%) amid high valuation multiples (P/E 34.5), but earnings beats and specialty tech growth offer upside. Risks include competitive pressures and margin compression from 32.1% in 2022 to 17.0% in 2025. Cash flow improved to $5.66B net in 2025, supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
